Immutep Announces Presentation of Quality of Life Data from EFTISARC-NEO Phase II Trial at ESMO 2026
Quality of life remained stable during neoadjuvant treatment with efti, pembrolizumab and radiotherapy, with statistically significant improvement after surgery
Covered in this story
Call it yourself
No calls on $NEO yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Neogenomics Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.